Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Non-covalent BTK inhibitor
Pirtobrutinib
Jaypirca · Pirto
A non-covalent BTK inhibitor for CLL/MCL — clearing high tumor burden raises tumor-lysis risk.
MildNon-covalent BTK inhibitor · approved 2023
Chronic lymphocytic leukemia / SLL (relapsed/refractory)Mantle-cell lymphoma (relapsed/refractory)
Signature kidney injury
Prerenal / Hemodynamic AKI
Direct nephrotoxicity is not characteristic. Tumor lysis syndrome is an identified risk when rapidly debulking high-burden lymphoid malignancy; renal-specific incidence is low and not well quantified. BTK inhibitors as a class are also associated with hypertension and bleeding/atrial fibrillation (non-renal).
Source: Mato et al., N Engl J Med 2023 (BRUIN)
Mechanism of kidney injury
Effective cytoreduction of bulky leukemia/lymphoma can precipitate tumor lysis syndrome — release of intracellular potassium, phosphate, and purines (metabolized to uric acid) with intratubular precipitation of uric-acid and calcium-phosphate crystals causing obstructive crystalline AKI, compounded by renal vasoconstriction. Associated volume shifts and reduced intake add a pre-renal component. The drug itself is not a recognized tubular toxin.
Clinical presentation
TLS labs — hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia — with rising creatinine, typically early after initiation in high-burden disease. Outside TLS, renal function is generally stable.
Onset
Early after initiation in high-burden disease (first cycle); TLS is usually a single early event.
Reversibility
Reversible
Anticancer mechanism
Reversible, non-covalent (non-C481-dependent) Bruton tyrosine-kinase inhibitor that retains activity against covalent-BTK-inhibitor-resistant disease, including C481S mutants. Approved for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle-cell lymphoma.
Management
Standard TLS management: aggressive IV hydration, rasburicase for hyperuricemia, correction of hyperkalemia/hyperphosphatemia/hypocalcemia, and renal replacement therapy if refractory. Supportive AKI care; the drug can usually be continued once TLS is controlled.
Risk factors
- High tumor burden / bulky or proliferative disease
- Pre-existing CKD
- Volume depletion
- Inadequate TLS prophylaxis
- Elevated baseline uric acid/LDH
Prevention
- Pre-treatment TLS risk assessment
- Hydration plus allopurinol (or rasburicase for high risk/elevated urate)
- Electrolyte, uric-acid and creatinine monitoring at initiation
- Avoid concurrent nephrotoxins during debulking
Note · Kidney risk is principally tumor-lysis-related and largely preventable; pirtobrutinib is not a recognized direct tubular toxin. Its non-covalent binding underlies activity after covalent-BTK-inhibitor failure, often in patients with substantial residual disease burden — the setting where TLS prophylaxis matters most.
Clinical depth
Renal dose adjustment
No dose adjustment for mild–moderate renal impairment; data in severe impairment/ESKD are limited (reduced dose has been studied in severe impairment per label). Hepatic and drug-interaction adjustments apply.
Dialyzability & ESKD dosing
Small molecule, highly protein-bound, hepatically metabolized; dialyzability not well characterized and removal unlikely to be clinically significant. Renal replacement therapy in this setting treats TLS, not drug levels.
Differential diagnosis
TLS crystalline AKI (high uric acid/phosphate, hypocalcemia) vs pre-renal AKI vs nephrotoxin; the urine sediment is bland-to-crystalline, distinguishing it from glomerular or interstitial drug lesions.
Monitoring
- Uric acid, potassium, phosphate, calcium and creatinine at initiation in high-burden disease
- CBC and tumor burden trend
- Blood pressure (class hypertension)
Key trials & series
- BRUIN (Mato NEJM 2023) phase I/II in CLL after covalent BTK inhibitors
- BRUIN MCL cohort (mantle-cell lymphoma)
Clinical pearls
- The renal risk is tumor lysis from effective debulking, not a tubular toxin — risk-stratify and pre-medicate before the first dose.
- Pirtobrutinib is often used after covalent-BTK failure in bulky disease — exactly the high-TLS-risk population.
- Hydration plus allopurinol (or rasburicase if high risk/elevated urate) prevents most crystalline AKI.
- Once TLS is controlled the drug can usually continue — the kidney event is early and self-limited.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of non-covalent btk inhibitors.
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- Atrial fibrillation, ventricular arrhythmia
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Bleeding, hypertension
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkPirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.Mato AR et al. · N Engl J Med 2023 · PMID 37407001Pivotal BRUIN efficacy/safety data in CLL after covalent BTK inhibitors.PMIDTumor Lysis Syndrome.Barbar T et al. · Adv Chronic Kidney Dis 2021 · PMID 35190110Onconephrology review of TLS-mediated crystalline AKI and prevention (hydration, rasburicase).PMIDTumour lysis syndrome.Howard SC et al. · Nat Rev Dis Primers 2024 · PMID 39174582Primer on TLS risk stratification, prevention and AKI mechanisms relevant to debulking lymphoid malignancy.PMIDRenal Side Effects of Novel Molecular Targeted Oncologic Agents.Fenoglio R et al. · G Ital Nefrol 2023 · PMID 38007829Onconephrology overview of renal effects of novel targeted agents, framing the low direct-nephrotoxicity profile of BTK inhibitors.PMIDCurrent Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features.Tonooka A et al. · J Nippon Med Sch 2021 · PMID 34840210Histologic survey of targeted-therapy renal complications contextualizing kinase-inhibitor renal safety.PMIDConventional Chemotherapy Nephrotoxicity.Gupta S et al. · Adv Chronic Kidney Dis 2021 · PMID 35190107Onconephrology reference for tumor-lysis and pre-renal AKI mechanisms in lymphoid malignancy.
Related agents
Other agents sharing the same signature kidney injury.